MoonLake Immunotherapeutics’ (MLTX) Buy Rating Reaffirmed at HC Wainwright

MoonLake Immunotherapeutics (NASDAQ:MLTX)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a research report issued to clients and investors on Tuesday,Benzinga reports. They currently have a $32.00 target price on the stock. HC Wainwright’s target price would suggest a potential upside of 102.66% from the company’s previous close.

A number of other research firms also recently weighed in on MLTX. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MoonLake Immunotherapeutics in a research note on Wednesday, October 8th. Zacks Research downgraded MoonLake Immunotherapeutics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, January 20th. UBS Group set a $24.00 price target on MoonLake Immunotherapeutics in a research note on Friday, January 9th. The Goldman Sachs Group lowered MoonLake Immunotherapeutics from a “neutral” rating to a “sell” rating and lifted their price objective for the company from $8.00 to $10.00 in a research note on Wednesday, January 14th. Finally, BTIG Research raised shares of MoonLake Immunotherapeutics from a “neutral” rating to a “buy” rating and set a $24.00 target price for the company in a research report on Friday, January 9th. Seven research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and five have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, MoonLake Immunotherapeutics currently has an average rating of “Hold” and an average price target of $25.77.

MoonLake Immunotherapeutics Trading Up 0.8%

Shares of MoonLake Immunotherapeutics stock opened at $15.79 on Tuesday. MoonLake Immunotherapeutics has a fifty-two week low of $5.95 and a fifty-two week high of $62.75. The business’s fifty day moving average is $14.62 and its two-hundred day moving average is $27.73. The company has a quick ratio of 8.50, a current ratio of 8.50 and a debt-to-equity ratio of 0.25. The firm has a market cap of $1.01 billion, a PE ratio of -4.76 and a beta of 1.20.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last released its earnings results on Wednesday, November 5th. The company reported ($1.10) EPS for the quarter, missing the consensus estimate of ($0.89) by ($0.21). During the same quarter in the previous year, the business posted ($0.56) earnings per share. Analysts anticipate that MoonLake Immunotherapeutics will post -1.79 earnings per share for the current year.

Insider Activity at MoonLake Immunotherapeutics

In other news, insider Kristian Reich sold 130,000 shares of the business’s stock in a transaction on Monday, December 8th. The shares were sold at an average price of $15.08, for a total transaction of $1,960,400.00. Following the transaction, the insider directly owned 72,908 shares of the company’s stock, valued at approximately $1,099,452.64. The trade was a 64.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Da Silva Jorge Santos sold 130,000 shares of the firm’s stock in a transaction on Monday, December 8th. The shares were sold at an average price of $15.08, for a total transaction of $1,960,400.00. Following the sale, the chief executive officer directly owned 2,948,577 shares of the company’s stock, valued at approximately $44,464,541.16. The trade was a 4.22% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 402,908 shares of company stock worth $5,987,162 over the last three months. 12.05% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On MoonLake Immunotherapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. UBS Group AG increased its position in shares of MoonLake Immunotherapeutics by 183.4% during the fourth quarter. UBS Group AG now owns 239,020 shares of the company’s stock worth $3,150,000 after acquiring an additional 154,673 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in MoonLake Immunotherapeutics by 129.6% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,592 shares of the company’s stock valued at $179,000 after purchasing an additional 7,673 shares in the last quarter. SG Americas Securities LLC increased its holdings in MoonLake Immunotherapeutics by 24.9% during the 4th quarter. SG Americas Securities LLC now owns 21,888 shares of the company’s stock worth $288,000 after purchasing an additional 4,362 shares during the last quarter. JPMorgan Chase & Co. raised its position in shares of MoonLake Immunotherapeutics by 342.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 174,161 shares of the company’s stock valued at $1,249,000 after purchasing an additional 134,764 shares in the last quarter. Finally, FNY Investment Advisers LLC acquired a new position in shares of MoonLake Immunotherapeutics in the 3rd quarter valued at approximately $28,000. 93.85% of the stock is owned by hedge funds and other institutional investors.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunomodulatory therapies for autoimmune and inflammatory diseases. The company leverages a proprietary platform designed to selectively modulate key immune cell populations, aiming to restore immune balance and reduce tissue damage with targeted biologic candidates.

Its lead asset, MLTX101, is a recombinant immune cell modulator in clinical development for myositis, including inclusion body myositis and dermatomyositis.